

Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

1. (currently amended) A composition comprising one or more peptides thirteen residues or less in length, wherein at least one of said one or more peptides comprises a CTL epitope selected from the group consisting of ~~from any of Tables 11-29:~~

DSVYGDTLER (SEQ ID NO: 527);

HTMLCMCCR (SEQ ID NO: 673);

LYNLLIRCF (SEQ ID NO: 846);

SVYGETLER (SEQ ID NO: 627);

LTEYVLDLY (SEQ ID NO: 139);

TFCCCKCDSTF (SEQ ID NO: 859);

AVCDKCLKFR (SEQ ID NO: 502);

ITDIILECVY (SEQ ID NO: 53);

LTDIEITCVY (SEQ ID NO: 55);

VYCKTVLEF (SEQ ID NO: 807); and

admixtures thereof.

2. (cancelled)
3. (cancelled)
4. (cancelled)
5. (currently amended) The composition of claim [[4]]1, further comprising an HTML peptide less than 50 residues in length, wherein said HTML peptide comprises an HTML

epitope, and further wherein said HTL peptide is admixed with or linked to said one or more peptides.

6. (currently amended) The composition of claim 1, further comprising a spacer molecule, wherein said spacer molecule is linked to at least one of said one or more peptides.

7. (currently amended) The composition of claim 1, further comprising a carrier, wherein said carrier is admixed with or linked to at least one of said one or more peptides.

8. (currently amended) The composition of claim 1, further comprising an MHC targeting sequence, wherein said MHC targeting sequence is admixed with or linked to at least one of said one or more peptides.

9. (currently amended) The composition of claim 1, further comprising a lipid, wherein said lipid is admixed with or linked to at least one of said one or more peptides.

10. (currently amended) The composition of claim 1, wherein at least one of the one or more peptides are incorporated as part of a liposome.

11. (previously presented) The composition of claim 1, wherein at least one of the one or more peptides is a heteropolymer.

12. (previously presented) The composition of claim 1, wherein at least one of the one or more peptides is a homopolymer.

13. (currently amended) The composition of claim 1, wherein at least one of the one or more peptides is a peptide from an antigen selected from the group consisting of prostate specific antigen (PSA), prostate specific membrane antigen (PSM), hepatitis B virus (HBV) antigen, hepatitis C virus (HCV) antigen, malignant melanoma antigen

(MAGE), Epstein-Barr virus, human immunodeficiency type 1 (HIV-1), human immunodeficiency type 2 (HIV-2), papilloma virus, Lassa virus, mycobacterium tuberculosis (MT), p53, murine p53 (mp53), CEA, HER2/neu, and tyrosine kinase related protein (TKP).

14. (cancelled)
15. (cancelled)
16. (cancelled)
17. (cancelled)
18. (previously presented) A diagnostic reagent comprising the composition of claim 1.
19. (cancelled)
20. (new) The composition of claim 1, wherein said CTL epitope is DSVYGDTLER (SEQ ID NO: 527).
21. (new) The composition of claim 1, wherein said CTL epitope is HTMLCMCCR (SEQ ID NO: 673).
22. (new) The composition of claim 1, wherein said CTL epitope is LYNLLIRCF (SEQ ID NO: 846).
23. (new) The composition of claim 1, wherein said CTL epitope is SVYGETLER (SEQ ID NO: 627).
24. (new) The composition of claim 1, wherein said CTL epitope is LTEYVLDLY (SEQ ID NO: 139).
25. (new) The composition of claim 1, wherein said CTL epitope is TFCCCKCDSTF (SEQ ID NO: 859).

26. (new) The composition of claim 1, wherein said CTL epitope is AVCDKCLKFR
(SEQ ID NO: 502).
27. (new) The composition of claim 1, wherein said CTL epitope is ITDIILECVY
(SEQ ID NO: 53).
28. (new) The composition of claim 1, wherein said CTL epitope is LTDIEITCVY
(SEQ ID NO: 55).
29. (new) The composition of claim 1, wherein said CTL epitope is VYCKTVLEF
(SEQ ID NO: 807).